AR090557A1 - DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2 - Google Patents
DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2Info
- Publication number
- AR090557A1 AR090557A1 ARP130101043A AR090557A1 AR 090557 A1 AR090557 A1 AR 090557A1 AR P130101043 A ARP130101043 A AR P130101043A AR 090557 A1 AR090557 A1 AR 090557A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- haloalkyl
- 6alkyl
- hydroxyalkyl
- alkoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Reivindicación 1: Un compuesto de la fórmula (1), caracterizado porque X es O ó S; R¹ es hidroxi, halógeno, alquilo C₁₋₆, haloalquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, cicloalquilo C₃₋₆, alcoxi C₁₋₆, haloalcoxi C₁₋₆, hidroxialquilo C₁₋₆, ciano, alcoxi C₁₋₆alquilo C₁₋₆, alcoxi C₁₋₆alcoxi C₁₋₆alquilo C₁₋₆, hidroxialcoxi C₁₋₆, hidroxialcoxi C₁₋₆alquilo C₁₋₆, hidroxialquenilo C₂₋₆, alqueniloxi C₂₋₆alquenilo C₂₋₆, haloalcoxi C₁₋₆alquilo C₁₋₆, haloalcoxi C₁₋₆-haloalquilo C₁₋₆, alcoxi C₁₋₆-haloalcoxi C₁₋₆, carboxi, alquil C₁₋₆-(C=O)-, alcoxi C₁₋₆-(C=O)-, alquil C₁₋₆-(C=O)-O-, haloalquil C₁₋₆-(C=O)-, haloalcoxi C₁₋₆-(C=O)-, (R⁶)₂N-, (R⁶)₂N-alquilo C₁₋₆, (R⁶)₂N-(C=O)-, R⁶-(C=O)-N(R⁶)-(C=O)-, R⁶-(O=S=O)-N(R⁶)-(C=O)-, R⁶-(C=O)-N(R⁶)-(O=S=O)-, R⁶-(O=S=O)-N(R⁶)-(O=S=O)-, (R⁶)₂N-N-, (R⁶)N=N-, (R⁶)₂N-O-, (R⁶)O-N(R⁶)-, alquil C₁₋₆-S-, alquenil C₂₋₆-S-alquenilo C₂₋₆, hidroxialquil C₁₋₆-S-, hidroxialquil C₁₋₆-S-alquilo C₁₋₆, alcoxi C₁₋₆alquil C₁₋₆-S-alquilo C₁₋₆, haloalquil C₁₋₆-S-, haloalquil C₁₋₆-S-alquilo C₁₋₆, haloalquil C₁₋₆-S-haloalquilo C₁₋₆, R⁶-(O=S)-, (R⁶)₂N-(O=S)-, R⁶-(O=S=O)-, (R⁶)₂N-(O=S=O)-, fenilo, fenil-O-, heteroarilo, heteroaril-O-, fenil-N(R⁶)-, heteroaril-N(R⁶)-, o heteroarilalquilo C₁₋₆; R² es H, hidroxi, oxo, fluoro, alquilo C₁₋₆, haloalquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆ cicloalquilo C₃₋₆, alcoxi C₁₋₆, haloalcoxi C₁₋₆, hidroxialquilo C₁₋₆, ciano, alcoxi C₁₋₆alquilo C₁₋₆, alcoxi C₁₋₆alcoxi C₁₋₆alquilo C₁₋₆, hidroxialcoxi C₁₋₆, hidroxialcoxi C₁₋₆alquilo C₁₋₆, hidroxialquenilo C₂₋₆, alqueniloxi C₂₋₆alquenilo C₂₋₆, haloalcoxi C₁₋₆alquilo C₁₋₆, haloalcoxi C₁₋₆-haloalquilo C₁₋₆, alcoxi C₁₋₆-haloalcoxi C₁₋₆, carboxi, alquil C₁₋₆-(C=O)-, -alcoxi C₁₋₆-(C=O)-, alquil C₁₋₆-(C=O)-O-, haloalquil C₁₋₆-(C=O)-, haloalcoxi C₁₋₆-(C=O)-, (R⁶)₂N-, (R⁶)₂N-alquilo C₁₋₆, (R⁶)₂N-(C=O)-, R⁶-(C=O)-N(R⁶)-(C=O)-, R⁶-(O=S=O)-N(R⁶)-(C=O)-, R⁶-(C=O)-N(R⁶)-(O=S=O)-, R⁶-(O=S=O)-N(R⁶)-(O=S=O)-, (R⁶)₂N-N-, (R⁶)N=N-, (R⁶)₂N-O-, (R⁶)O=N-, alquil C₁₋₆-S-, alquenil C₂₋₆-S-alquenilo C₂₋₆, hidroxialquil C₁₋₆-S-, hidroxialquil C₁₋₆-S-alquilo C₁₋₆, alcoxi C₁₋₆alquil C₁₋₆-S-alquilo C₁₋₆, haloalquil C₁₋₆-S-, haloalquil C₁₋₆-S-alquilo C₁₋₆, haloalquil C₁₋₆-S-haloalquilo C₁₋₆, R⁶-(O=S)-, (R⁶)₂N-(O=S)-, R⁶-(O=S=O)-, (R⁶)₂N-(O=S=O)-, fenilo, fenil-O-, heteroarilo, heteroaril-O-, fenil-N(R⁶)-, heteroaril-N(R⁶)-, o heteroarilalquilo C₁₋₆; R³ es H, alquilo C₁₋₆, haloalquilo C₁₋₆, alcoxi C₁₋₆, haloalcoxi C₁₋₆, hidroxialquilo C₁₋₆, alcoxi C₁₋₆alquilo C₁₋₆, o cicloalquilo C₃₋₆; R⁴ es H, hidroxi, halógeno, alquilo C₁₋₂, o haloalquilo C₁₋₂; R⁵ es H, hidroxi, halógeno, alquilo C₁₋₆, haloalquilo C₁₋₂, cicloalquilo C₃₋₆, alcoxi C₁₋₆, haloalcoxi C₁₋₆, hidroxialquilo C₁₋₆, fenilo, o heteroarilo; y R⁶ es, independientemente en cada ocurrencia, H, alquilo C₁₋₆, alcoxi C₁₋₆alquilo C₁₋₆, hidroxialquilo C₁₋₆, haloalquilo C₁₋₆ o R⁶ y R⁶ forman, junto con los átomos a los cuales ellos se enlazan, un anillo carbocíclico saturado o insaturado de 4, 5, 6 ó 7 elementos condensado o un anillo heterocíclico saturado o insaturado de 4, 5, 6 ó 7 elementos condensado que contiene 1 ó 2 heteroátomo(s) seleccionados de N, O y S, caracterizado porque dicho anillo carbocíclico o heterocíclico es no sustituido o sustituido con 1 ó 2 sustituyente(s) cada uno siendo independientemente hidroxi, oxo, halógeno, alquilo C₁₋₆, hidroxialquilo C₁₋₆, o haloalquil C₁₋₆-; o R¹ y R² forman, junto con los átomos de carbono en el anillo a los cuales ellos están enlazados, un anillo carbocíclico saturado o insaturado de 4, 5, 6 ó 7 elementos condensado o un anillo heterocíclico saturado o insaturado de 4, 5, 6 ó 7 elementos condensado que contiene 1 ó 2 heteroátomo(s) seleccionados de N, O y S, caracterizado porque dicho anillo carbocíclico o heterocíclico es no sustituido o sustituido con 1 ó 2 sustituyente(s) cada uno siendo independientemente hidroxi, oxo, halógeno, alquilo C₁₋₆, alcoxi C₁₋₆alquilo C₁₋₆, hidroxialquilo C₁₋₆, o haloalquilo C₁₋₆; o R² y R³ forman, junto con los átomos de carbono en el anillo a los cuales ellos están enlazados, un anillo carbocíclico saturado o insaturado de 4, 5, 6 ó 7 elementos condensado o un anillo heterocíclico saturado o insaturado de 4, 5, 6 ó 7 elementos condensado que contiene 1 ó 2 heteroátomo(s) seleccionados de N, O y S, caracterizado porque dicho anillo carbocíclico o heterocíclico es no sustituido o sustituido con 1 ó 2 sustituyente(s) cada uno siendo independientemente hidroxi, oxo, halógeno, alquilo C₁₋₆, alcoxi C₁₋₆alquilo C₁₋₆, hidroxialquilo C₁₋₆, o haloalquilo C₁₋₆; o una sal o éster del mismo aceptable desde el punto de vista farmacéutico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261619109P | 2012-04-02 | 2012-04-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR090557A1 true AR090557A1 (es) | 2014-11-19 |
Family
ID=48224812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130101043 AR090557A1 (es) | 2012-04-02 | 2013-03-27 | DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US9249127B2 (es) |
| EP (1) | EP2834233B1 (es) |
| JP (1) | JP6427096B2 (es) |
| KR (1) | KR102104228B1 (es) |
| CN (1) | CN104220437B (es) |
| AR (1) | AR090557A1 (es) |
| AU (1) | AU2013244859B2 (es) |
| BR (1) | BR112014023957B1 (es) |
| CA (1) | CA2868611C (es) |
| DK (1) | DK2834233T3 (es) |
| ES (1) | ES2674945T3 (es) |
| FR (1) | FR22C1005I2 (es) |
| HR (1) | HRP20181203T1 (es) |
| HU (2) | HUE039290T2 (es) |
| IL (1) | IL234663B (es) |
| LT (2) | LT2834233T (es) |
| MX (1) | MX358429B (es) |
| NL (1) | NL301160I2 (es) |
| NO (1) | NO2022002I1 (es) |
| PL (1) | PL2834233T3 (es) |
| PT (1) | PT2834233T (es) |
| RU (1) | RU2642065C2 (es) |
| SI (1) | SI2834233T1 (es) |
| TW (1) | TWI620746B (es) |
| WO (1) | WO2013150173A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2015152196A1 (ja) * | 2014-03-31 | 2017-04-13 | 東レ株式会社 | イミダゾリン誘導体及びその医薬用途 |
| JP6657241B2 (ja) * | 2015-02-11 | 2020-03-04 | サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | Ｃｎｓ疾患を治療するための１−複素環イソクロマニル化合物およびアナログ |
| CN105646306B (zh) * | 2015-12-11 | 2020-06-30 | 广东莱佛士制药技术有限公司 | 一种4-甲硫基苯乙酸的制备方法 |
| HUE059849T2 (hu) | 2017-12-01 | 2023-01-28 | Orion Corp | Eljárás 2-(5-metoxi-izokromán-1-il)-4,5-dihidro-1H-imidazol és annak hidrogénszulfát-sója elõállítására |
| CN110272407B (zh) * | 2019-07-22 | 2021-02-05 | 河北省农林科学院经济作物研究所 | 一种用于降血压的天然异色满酮类化合物 |
| JP2024510021A (ja) * | 2021-03-19 | 2024-03-05 | オリオン コーポレーション | タシピミジン製剤およびその使用 |
| KR20240138110A (ko) | 2022-01-24 | 2024-09-20 | 오리온 코포레이션 | 이소크로만-이미다졸 구조화 알파-2a 아드레날린 수용체 작용제의 신규한 설페이트 염 형태 |
| KR20240144336A (ko) | 2022-02-04 | 2024-10-02 | 오리온 코포레이션 | 이소크로만-이미다졸 구조의 알파-2a 아드레노셉터 작용제의 신규한 염 형태 |
| IL319889A (en) | 2022-09-28 | 2025-05-01 | Orion Corp | Combination therapy with a CYP2D6 inhibitor and taspimidin |
| CN117343036A (zh) * | 2023-03-20 | 2024-01-05 | 江苏联环药业股份有限公司 | 异苯并二氢吡喃类化合物及其药物组合物和应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1247008B (de) * | 1965-10-05 | 1967-08-10 | Huels Chemische Werke Ag | Thermoplastische Massen zur Herstellung von vergilbungsfreien antielektrostatischen Formkoerpern aus Polyolefinen |
| US3438995A (en) | 1968-01-08 | 1969-04-15 | Melville Sahyun | Diazaheterocyclic substituted benz-oxaheterocyclic compounds |
| EP0166937B1 (en) * | 1984-06-06 | 1991-08-28 | Abbott Laboratories | Adrenergic compounds |
| IL136388A0 (en) * | 1997-12-04 | 2001-06-14 | Allergan Sales Inc | Substituted imidazole derivatives having agonist-like activity at alpha 2b or 2b/2c adrenergic receptors |
| FI20000073A0 (fi) * | 2000-01-14 | 2000-01-14 | Orion Yhtymae Oy | Uusia imidatsolijohdannaisia |
| ATE458732T1 (de) | 2006-01-27 | 2010-03-15 | Hoffmann La Roche | Verwendung von 4-imidazol-derivaten für zns- erkrankungen |
| AU2007209382A1 (en) * | 2006-01-27 | 2007-08-02 | F. Hoffmann-La Roche Ag | Use of 2-imidazoles for the treatment of CNS disorders |
| US20080020076A1 (en) * | 2006-07-21 | 2008-01-24 | Khem Jhamandas | Methods and Therapies for Potentiating a Therapeutic Action of an Alpha-2 Adrenergic Receptor Agonist and Inhibiting and/or Reversing Tolerance to Alpha-2 Adrenergic Receptor Agonists |
-
2013
- 2013-03-27 AR ARP130101043 patent/AR090557A1/es active IP Right Grant
- 2013-03-28 WO PCT/FI2013/000013 patent/WO2013150173A1/en not_active Ceased
- 2013-03-28 MX MX2014011851A patent/MX358429B/es active IP Right Grant
- 2013-03-28 BR BR112014023957-6A patent/BR112014023957B1/pt active IP Right Grant
- 2013-03-28 JP JP2015503903A patent/JP6427096B2/ja active Active
- 2013-03-28 LT LTEP13719297.7T patent/LT2834233T/lt unknown
- 2013-03-28 RU RU2014144284A patent/RU2642065C2/ru active
- 2013-03-28 ES ES13719297.7T patent/ES2674945T3/es active Active
- 2013-03-28 EP EP13719297.7A patent/EP2834233B1/en active Active
- 2013-03-28 AU AU2013244859A patent/AU2013244859B2/en active Active
- 2013-03-28 CA CA2868611A patent/CA2868611C/en active Active
- 2013-03-28 DK DK13719297.7T patent/DK2834233T3/en active
- 2013-03-28 PT PT137192977T patent/PT2834233T/pt unknown
- 2013-03-28 SI SI201331024T patent/SI2834233T1/en unknown
- 2013-03-28 KR KR1020147027610A patent/KR102104228B1/ko active Active
- 2013-03-28 HU HUE13719297A patent/HUE039290T2/hu unknown
- 2013-03-28 PL PL13719297T patent/PL2834233T3/pl unknown
- 2013-03-28 CN CN201380018776.XA patent/CN104220437B/zh active Active
- 2013-03-28 US US14/389,466 patent/US9249127B2/en active Active
- 2013-03-28 HR HRP20181203TT patent/HRP20181203T1/hr unknown
- 2013-03-29 TW TW102111298A patent/TWI620746B/zh active
-
2014
- 2014-09-15 IL IL234663A patent/IL234663B/en active IP Right Grant
-
2022
- 2022-01-27 NO NO2022002C patent/NO2022002I1/no unknown
- 2022-01-31 NL NL301160C patent/NL301160I2/nl unknown
- 2022-01-31 FR FR22C1005C patent/FR22C1005I2/fr active Active
- 2022-02-02 HU HUS2200005C patent/HUS2200005I1/hu unknown
- 2022-02-03 LT LTPA2022001C patent/LTC2834233I2/lt unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR090557A1 (es) | DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2 | |
| AR104884A1 (es) | Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj | |
| AR102177A1 (es) | Compuestos de heteroarilo como inhibidores de btk y usos de los mismos | |
| PE20151752A1 (es) | Amidas heterociclicas como inhibidores de cinasas | |
| AR098912A1 (es) | Inhibidores de syk | |
| AR099177A1 (es) | Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
| AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR103138A1 (es) | Compuestos de heteroarilo como inhibidores de la irak y usos de los mismos | |
| AR097866A1 (es) | Derivados de 4-azaindol | |
| AR089671A1 (es) | 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| AR098414A1 (es) | PIPERAZINAS DE PIRAZOLO SUSTITUIDO COMO INHIBIDORES DE CASEÍNA QUINASA 1 d/e | |
| ES2669189T3 (es) | Compuestos de carbazol útiles como inhibidores del bromodominio | |
| AR090760A1 (es) | Compuestos de benzotiazol y su uso contra el virus de hiv | |
| AR094300A1 (es) | Derivados de quinolonas | |
| AR094812A1 (es) | Derivado de piridina monocíclico como inhibidor del fgfr | |
| AR093937A1 (es) | Compuestos quimicos | |
| AR090086A1 (es) | COMPUESTO DE 1H-INDAZOL-3-CARBOXAMIDA COMO INHIBIDORES DE LA GLUCOGENO SINTASA CINASA 3 b | |
| AR107321A1 (es) | Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos | |
| AR101359A1 (es) | Derivados de 2-oxa-5-azabiciclo[2.2.1]heptan-3-ilo | |
| AR097894A1 (es) | Inhibidores terapéuticos de cdk8 o uso de los mismos | |
| AR096153A1 (es) | Derivados de pirrolo[2,3-d]pirimidina | |
| AR100724A1 (es) | Derivados de quinolina y su uso en enfermedades neurodegenerativas | |
| ES2568909T3 (es) | Novedosos compuestos antagonistas del receptor de la neuroquinina 1 | |
| AR089814A1 (es) | Compuestos que modulan la actividad de los proteasomas | |
| AR098965A1 (es) | Derivados de sulfonamidas tricíclicas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |